Neolytica - A QPharma Company
Panagiotis Gerolymatos is a highly experienced data science and education professional currently serving as the Lead Data Science Architect at Neolytica, a QPharma Company, since November 2019, after previously holding the role of Senior Data Scientist. Prior to Neolytica, Panagiotis worked as a Data Scientist at OCM Digital Media from June 2018 to September 2021, and spent a decade as a Special Education Math Teacher at the Public Education of Corfu. Early career experience includes serving as an Information Systems Engineer at the Computer Technology Institute and Press "Diophantus" from January 2004 to September 2010. Panagiotis holds a Master of Science in Information Systems from Ionian Panepistimion, a Master of Science in Wireless Communications and Digital Systems from the University of Pireus, and a Bachelor's degree in Mathematics from the University of Patras.
This person is not in any offices
Neolytica - A QPharma Company
A subsidiary of QPharma, Neolytica brings solutions and a portfolio of products that leverage cutting edge technologies like AI and Data Analytics to deliver significant value in strategic and operational aspects of Medical Affairs, Market Access, Commercial Marketing and Commercial Sales. Our offerings portfolio includes: Ti Expert : This technology and consulting solution brings comprehensive access to data about highly qualified and validated medical professionals, including professional spheres of influence, social relationships, and promotional activities. NotifyMe : A Healthcare KOL engagement service with email alerts. An application that enables enterprise-scale social listening and provides actionable alerts on healthcare stakeholders in a desired therapeutic area. Ti Risk : Dependence on Opioid has increased burden on patients, employers, insurers, society, and the health care system. Our product aims to address this by identifying prescribers and patients that are potentially involved in diversion of opioids by following patient journey and prescriber behaviour, along with supplementary secondary research – Real-time and At-risk scoring analysis. For more details, visit - www.neolytica.ai